Login to Your Account



Boehringer NASH trial start adds €18M to Pharmaxis till

By Michael Fitzhugh
Staff Writer

Thursday, August 24, 2017

Boehringer Ingelheim GmbH has started a phase IIa trial in nonalcoholic steatohepatitis seeking insight on four different doses of BI-1467335, an anti-inflammatory drug it acquired from Sydney-based Pharmaxis Ltd.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription